Identification of predictive Biomarkers for successful salvage surgeries on PSMA-PET-positive oligometastatic Prostate cancer relapses (BioPoP)
- Conditions
- C61Malignant neoplasm of prostate
- Registration Number
- DRKS00020820
- Lead Sponsor
- Martini-Klinik am UKE GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 174
Inclusion Criteria
• Patients in good general condition with an life expectancy> 10 years
• presence of prostate cancer recurrence
• Detection of PSMA PET positive lymph node or soft tissue metastases
Exclusion Criteria
• Contraindication to surgery
• Clinical suspicion of a systemic disease in PSMA PET
• Age of the PSMA PET examination > 4 months at the time of surgery
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary correlation of the results from the biomarker measurements with: Rate of complete biochemical response (cBR: PSA <0,2ng/ml) 6 months after salvage lymphadenectomy without adjuvant prostate cancer-specific treatment (e.g. drugs, radiotherapy, surgery)
- Secondary Outcome Measures
Name Time Method